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A B S T R A C T   
Hypertension of SHR appears at an early age and progressively increases. This study aimed to evaluate the effect 
of lycopene in SHR with mild hypertension (young rats) or with high level of hypertension (adult rats). Four- 
weeks treatment with 10 mg/kg/day of lycopene progressively decreased blood pressure in young (from 144 
± 2 to 119 ± 3 mmHg) and adult (from 177 ± 5 to 159 ± 7 mmHg) SHR. Heart and renal hypertrophy and 
fibrosis were increased in adult compared to young SHR and lycopene, regardless of the age of the rats, improved 
the injury in both organs. Although aging induced morphological and functional alterations in the aorta, the 
treatment was only effective in preventing the former. Lycopene helped to improve all the parameters linked to 
oxidative stress determined in this study. In conclusion, lycopene treatment improved the age-associated harmful 
changes in hypertension, cardiovascular and renal remodelling, and indicators of oxidant-antioxidant systems in 
both young and adult SHR.   
1. Introduction 
Aging is a progressive and continual natural process that results in 
decreased physiologic functions across all organ systems. These physi-
ological changes result in development in chronic and inflammatory 
diseases that dramatically increase the risk of mortality (Buford, 2016). 
Hypertension associated with aging is recognized as major risk factor for 
the development of cardiovascular diseases (CVD) (World Health Or-
ganization, 2017). This pathological state is a multifactorial, complex 
disorder involving various organ systems (Silva et al., 2017). In general, 
the elevation of blood pressure leads to vascular dysfunction, increased 
arterial stiffness, cardiac and renal alterations as well as changes in the 
redox state (Montezano et al., 2015; Zhou et al., 2017). Hypertension is a 
global public health problem therefore, prevent or delay its develop-
ment as well as find an effective treatment is very important. In this 
sense, antihypertensive therapy has a relevant role, resulting in reduc-
tion in the incidence of other associated CVD pathologies, such as stroke, 
myocardial infarction and heart failure, among others (Touyz et al., 
2018). Recent studies have been reporting the action of new antihy-
pertensive agents, demonstrating the effectiveness at the level of the 
cardiovascular system (Llorens-Cortes & Touyz, 2020; Sánchez-Rivera 
et al., 2016). 
Non-pharmacological options play a central role in the treatment of 
hypertension. Several epidemiologic and prospective studies have pro-
vided convincing evidence that the Mediterranean diet (rich in fruits and 
vegetables, limiting the intake of red meats and using a healthy source of 
fat) results in a lower risk of developing CVD (Babio et al., 2014; 
Ferreira-Santos et al., 2018). In this regard, dietary intake of lycopene, a 
carotenoid compound found in large quantities in various fruits and 
vegetables included in the Mediterranean diet, has received consider-
able scientific interest due to its high antioxidant capacity (Anlar & 
Bacanli, 2020; Arain, Zhuang, Hassan, & Saeed, 2018; Müller, Caris- 
Veyrat, Lowe, & Böhm, 2016). Lycopene supplementation shown 
effectiveness for prevention or treatment of certain chronic pathologies, 
such as hypertension, cancer, diabetes, dyslipidemia, etc. (Ferreira- 
Santos et al., 2018; Friedman, 2013; Jiang, Guo, & Hai, 2016; 
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Roohbakhsh, Karimi, & Iranshahi, 2017; Thies, Mills, Moir, & Masson, 
2017). Many studies have shown that lycopene exhibits cardiovascular 
effects in humans and animals and provides a protection against damage 
caused by reactive oxygen species (ROS), regulating redox status and 
antioxidant enzyme activity and improving the plasma lipid profile 
(Bose & Agrawal, 2007; Chen, Song, & Zhang, 2013; Ferreira-Santos 
et al., 2018; Mordente et al., 2011; Paran, Novack, Engelhard, & 
Hazan-Halevy, 2009). 
Given the important role of oxidative stress in the pathogenesis of 
many clinical conditions and aging, antioxidant therapy could be 
interesting to improve the health of the population. In this way, our 
research group has been developing studies of drugs and dietary modi-
fications (intake of antioxidants and bioactive peptides), for the treat-
ment and prevention of CVD, such as hypertension, dyslipidemia and 
diabetes. 
This research work was carried out in young and adult SHR rats in 
order to verify that the cardiovascular alterations caused by hyperten-
sion worsened with age. In this context, our objective was to study 
whether both the antihypertensive effect of lycopene and its benefits on 
cardiovascular disorders caused by high blood pressure were different 
depending on the severity of these damages caused by aging. 
2. Materials and methods 
2.1. Experimental protocol 
All the experiments were performed according to the European 
Union guidelines for the ethical care and use of laboratory animals and 
the protocol was approved by the Bioethics Committee of University of 
Salamanca (Register N◦: 006N◦201400039292). Twenty-eight male SHR 
(Janvier Labs, Le Genest Saint Isle, France), half 7-weeks old and the 
other fourteen 21 weeks old, were housed in boxes of 3–4 rats and 
maintained at a temperature of 23 ◦C with 12 h light/dark cycles. Rats 
were fed on a solid standard diet (Global Diet 2014, Harlan Laboratories, 
Inc., Indianapolis, IN, USA) and tap water with ad libitum intake. 
After two weeks of adaptation, baseline blood pressure measure-
ments were performed. The systolic blood pressure (SBP) in conscious 
rats was measured by a CODA tail-cuff blood pressure system (Kent 
Scientific, Torrington, CT, USA), using the same methodology previ-
ously reported by us (Ferreira-Santos et al., 2018). 
Thereafter, young SHR (with mild hypertension) and adult SHR 
(with high level of hypertension) were distributed in the following 
groups of seven animals each. Non-treated groups (SHR): 1) young (9 
weeks) and 2) adult (21 weeks) rats received tap water. 
Lycopene treated groups (SHR-LYC): 1) young (9 weeks) and 2) adult 
(21 weeks) rats received lycopene dissolved in drinking water. 
Lycopene concentration was adjusted to daily water consumption to 
achieve a correct dosage of 10 mg/kg/day. This dose of lycopene was 
previously used in other studies of our group, showing effects on the 
cardiovascular system (Ferreira-Santos, Aparicio, Carrón, Montero, & 
Sevilla, 2020; Ferreira-Santos et al., 2018). 
The BW and SBP were monitored weekly in all groups during the 
experimental period (4 weeks). After this time, animals were anaes-
thetized with sodium pentobarbital (60 mg/kg BW, i.p.). Blood samples 
were collected, centrifuged, and the plasma was stored at –80 ◦C until 
use. Heart, kidney, liver and thoracic aorta were immediately harvested, 
placed in chilled Krebs buffer (composition in mM: NaCl, 118; KCl, 4.7; 
CaCl2, 2.5; KH2PO4, 1.2; MgSO4, 1.2; NaHCO3, 25 and glucose, 11, pH =
7.4) and appropriately processed for further studies. 
2.2. Hypertrophy and fibrosis 
After sacrifice, the heart, kidney and aorta were removed and placed 
immediately in Krebs solution, gassed with carbogen (5% CO2, 95% O2) 
and kept at 37 ◦C to remove excess blood. For the determination of left 
ventricular hypertrophy (LVH) index, the atria were removed from the 
heart and all the epicardial fat was scraped off, the right and left ven-
tricles were separated, regarding the interventricular septum as an in-
tegral part of the left ventricle, and weighed. To determine the renal 
hypertrophy (RH) index, the left kidney was properly dried with filter 
paper to remove excess Krebs solution and all fat was removed. After-
wards the kidney was weighed. Both, ventricular and renal hypertrophy 
were calculated as an index using organ weight/BW ratio. 
Sections of ventricle, kidney and a portion of the aorta were fixed in 
10% formaldehyde and then processed for paraffin embedding. Slices of 
5-µm were stained with Sirius-red collagen-specific stain or 
hematoxylin-eosin and examined under light microscopy. At least eight 
areas from each preparation were captured using a high-resolution 
digital camera with attached video camera (Olimpus BX50 and DP50, 
respectively, Tokyo, Japan). 
Adobe Photoshop® CS3 software was used to quantified the collagen 
in histologic sections, and the percentage of cardiac and renal interstitial 
fibrosis was determined for each image as the ratio of the collagen 
surface area to the total area (5–7 fields for each section were 
measured). 
Estimation of cardiac and renal collagen was also performed by 
measuring the content of hydroxyproline using a spectrophotometric 
method reported elsewhere (Sauzeau et al., 2006). Total collagen was 
calculated assuming that collagen contains 12.7% hydroxyproline. 
Morphometric parameters of arteries were determined using aortic 
slices, the internal and external perimeters of the medial layer were 
measured using the ImageJ software, and internal and external radii (Ri 
and Re respectively) calculated according to the formula: perimeter =
2πR, where 2Ri is the internal diameter (L) and Re − Ri is the medial 
thickness (Wm). The medial cross-sectional area (CSAm) was calculated 
as: CSAm = π(Re2 − Ri2). 
2.3. Vascular reactivity in aorta 
Vascular reactivity was performed in isolated aorta rings (3 mm in 
length) using a methodology reported previously by our group (Ferreira- 
Santos et al., 2018). Rings were placed in organ bath with Krebs solution 
at 37 ◦C aerated with carbogen. The preparations were precontracted 
with phenylephrine (PE, 10− 6 M) and at the steady maximal contraction, 
cumulative concentration–response curves were obtained for acetyl-
choline (ACh, 10− 8–10− 4 M) or sodium nitroprusside (SNP, 10− 8–10− 5 
M). 
Each curve was obtained in different rings, and responses to ACh and 
SNP were expressed as percentage of PE contraction. 
2.4. Oxidative stress parameters 
2.4.1. Detection of superoxide anion 
The superoxide anion (O2
•¡) produced by NADPH-oxidases is the 
main ROS in vessels. O2
•¡ production was assessed by lucigenin- 
enhanced chemiluminescence assay in segments of thoracic aorta 
stimulated by nicotinamide adenosine dinucleotide phosphate (NADPH, 
10¡4 M) using a luminometer (LUMAT LB-9507, Berthold Technologies, 
Bad Wildbad, Germany). The results of O2
•¡ production were expressed 
as relative luminescence units (RLU)/min/mg dry tissue. 
2.4.2. Lipid peroxidation determination 
The formation of products of lipid peroxidation was quantified in 
plasma using the thiobarbituric acid-reactive substances (TBARS) 
method, as reported previously by us (Ferreira-Santos et al., 2018) and 
results were expressed as malondialdehyde (MDA) concentration 
(nmol/mL). 
2.4.3. Antioxidant enzymes 
The activity of endogenous antioxidant enzymes (superoxide dis-
mutase (SOD) and glutathione peroxidase (GSH-PX)) was assessed in 
liver homogenates previously centrifuged (1200 rpm for 30 min at 4 ◦C) 
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to remove crude fractions. The supernatants were used to carry out the 
determination of enzymatic activity by spectrophotometric methods 
using commercially available assay kits (Sigma-Aldrich, USA). Total 
proteins were measured by the Bradford method, and results of enzy-
matic activity were reported as U/mg protein. 
2.5. Statistical analysis 
Values are expressed as the mean ± standard error of the mean 
(SEM). GraphPad Prism® software (version 5.0; GraphPad Software, 
Inc., San Diego, CA, USA) was used for calculations, fitting and statistical 
analysis. Comparison of concentration–response curves of ACh and SNP 
were performed according to the extra sum of squares F-test principle. 
The level of statistical significance was determined by one-way analysis 
of variance (ANOVA) followed by Bonferroni’s test for multiple com-
parisons and two-way ANOVA for blood pressure data. Significance was 
accepted at P < 0.05. 
2.6. Chemical compounds 
Lycopene (Redivivo®, 10% CWS/S-TG, DSM Nutritional Products, 
USA). Acetylcholine chloride (PubChem CID: 6060); phenylephrine 
hydrochloride (PubChem CID: 5284443); Sirius-red (PubChem CID: 
5464587); sodium nitroprusside (PubChem CID: 11953895); thio-
barbituric acid (PubChem CID: 2723628), trichloroacetic acid (Pub-
Chem CID: 6421), nicotinamide adenosine dinucleotide phosphate 
(PubChem CID: 5884) and lucigenin (PubChem CID: 65099) were pur-
chased from Sigma-Aldrich (St. Louis, MO, USA). All other chemicals 
were analytical grade. Stock solutions were prepared in ultrapure water, 
stored at − 20 ◦C and appropriate dilutions were made on the day of the 
experiments. 
3. Results 
3.1. Systolic blood pressure 
Initially, young rats had a mild hypertension state with SBP values 
around 140 mmHg, while adult animals had SBP values above 170 
mmHg, ie, established hypertension. A slight increase in these values 
throughout the study was observed in both groups of non-treated rats. 
As shown in Fig. 1A, the treatment with lycopene progressively 
decreased SBP in young SHR (from 144 ± 2 mmHg to 119 ± 3 mmHg at 
the end of treatment, P < 0.001) and in adult SHR (from 177 ± 5 mmHg 
to 159 ± 7 mmHg at the end of treatment, P < 0.01). 
At the end of treatment, BW was similar between treated and non- 
treated groups for young and adult SHR, respectively (Fig. 1B). 
3.2. Hypertrophy and fibrosis 
3.2.1. Heart 
LVH index in adult SHR was shown to be significantly higher 
compared to young rats (2.71 ± 0.03 mg/g BW vs. 2.55 ± 0.01 mg/g BW, 
respectively, P < 0.05) (Fig. 2A). 
According to SBP and LVH results, hypertension associated with 
aging leads to a significant increase in collagen deposition, quantified by 
interstitial fibrosis stained with Sirius red in histological slices (Fig. 2B 
and D) and the content of hydroxyproline present in the left ventricle 
homogenates (Fig. 2C). The lycopene supplement was effective in 
reducing hypertrophy and fibrosis. 
3.2.2. Kidney 
RH index in adult rats was shown to be significantly higher compared 
to young rats (3.31 ± 0.05 mg/g BW vs. 3.13 ± 0.06 mg/g BW, 
respectively, P < 0.05) (Fig. 3A). Also the collagen deposition was 
increased as can be seen in interstitial fibrosis quantified in the histo-
logical sections of the kidney as percentage (Fig. 3B and D) or in kidney 
homogenates as hydroxyproline content (Fig. 3C). The lycopene treat-
ment showed a significant reduction of renal hypertrophy and was able 
to decrease the collagen deposition. 
3.2.3. Aorta 
According to the other factors studied, the morphology of the aorta 
was also altered with the age. In Table 1 and Fig. 4 it is possible to 
observe a significant increase in all parameters studied (L, Wm, CSAm 
and Wm/L) in adult animals. The treatment with lycopene significantly 
prevented the morphometric alterations in the thoracic aorta, 
decreasing the Wm, CSAm and Wm/L in relation to the respective young 
and adult SHR control group. Lycopene treatment increased the aorta 
lumen in young rats, but no changes were observed in adult rats. 
3.3. Vascular reactivity 
As shown in Fig. 5A and B, the aging promotes vascular dysfunction 
manifested in the reduction of endothelial-dependent vasorelaxation to 
ACh (Emax, 80.8 ± 1.6 % for young rats vs. 52.7 ± 1.6 % for adult rats, P 
< 0.001) and endothelium-independent relaxation induced by SNP 
(Emax, 94.5 ± 2.0 % for young rats vs. 82.6 ± 2.6 % for adult rats, P <
0.01) on aortic rings of SHR. Treatment with lycopene was not able to 
improve the impairment of relaxation responses caused by aging. 
Moreover, the contractile response to PE was similar in the two 
Fig. 1. Systolic blood pressure (SBP) (A), and body weight (B) in young and adult spontaneously hypertensive rats (SHR) and SHR treated with 10 mg/kg/day of 
lycopene (SHR-LYC). Values are expressed as mean ± SEM (n = 7). ##P < 0.01 and ###P < 0.001 vs. young SHR; *P < 0. 05, **P < 0. 01 and ***P < 0.001 vs. the 
corresponding SHR without treatment. 
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groups (young and adult rats), and the intake of lycopene during the 4 
weeks did not significantly modify any response (data not shown). 
3.4. Parameters of oxidative stress 
O2
•¡ production stimulated by NADPH was higher in aortic rings of 
adult SHR control group compared to young animals (5723 ± 523 RLU/ 
min/mg vs. 2543 ± 232 RLU/min/mg, respectively, P < 0.001). Chronic 
treatment with lycopene decreased O2
•¡ production. This effect was 
more visible in adult animals, where ROS production was higher than in 
younger animals (Fig. 6A). 
Fig. 6B shows that adult SHR rats had a significant elevation of MDA 
content compared to the young SHR group (4.6 ± 0.1 nmol/mL vs. 3.9 ±
0.2 nmol/mL, P < 0.05). Moreover, lycopene significantly attenuated 
the plasmatic MDA levels in both groups of animals (3.8 ± 0.1 nmol/mL 
for adult and 3.2 ± 0.1 nmol/mL for young rats). 
3.5. Activity of antioxidant enzymes 
The enzymatic activities of SOD and GSH-PX in the liver homoge-
nates were determined. As shown in Table 2, untreated SHR animals 
have similar values of antioxidant enzymes activity. Treatment with 
lycopene in young and adult SHR rats increased significantly the activity 
of SOD and GSH-PX. 
4. Discussion 
This study examines, for the first time, the effect of the lycopene on 
the cardiac, vascular and renal alterations using the SHR model and 
comparing two states of the hypertension development associated to the 
aging. 
Aging is a primary risk factor for many diseases and in particular for 
CVD and its derived morbidity and mortality (Izzo et al., 2021). 
Oxidative stress is involved in the development of many degenerative 
and chronic age-related disorders: CVD, chronic kidney disease, neuro-
degenerative diseases, cancer, etc. ROS play a physiological role in the 
cardiovascular system, controlling endothelial function, vascular tone, 
and cardiac function, and a pathophysiological role in inflammation, 
hypertrophy, proliferation, apoptosis, migration, fibrosis, angiogenesis, 
and rarefaction, all of which are important processes contributing to 
endothelial dysfunction and cardiovascular remodeling in hypertension 
and other CVD (Montezano & Touyz, 2012). 
Among other complications, hypertension can cause serious damage 
to the heart, manifested by ventricular hypertrophy, enlargement of 
cardiomyocytes and collagen deposition. In addition, hypertensive 
process can cause kidney damage and endothelial dysfunction, directly 
linked to the production of ROS, leading to so-called oxidative stress 
(Silva et al., 2017; World Health Organization, 2017). 
Different rat genetic models of hypertension have been used in ge-
netic, (patho)physiological and pharmacological studies, but the most 
commonly studied is the SHR (Lerman, Kurtz, Touyz, Ellison, Chade, 
Crowley, & Coffman, 2019). In this strain the hypertension appears early 
and progressively increases over time. Ours results confirm that age in 
SHR was associated with elevation of SBP, young rats had blood pressure 
values coincident with mild hypertension while adults were clearly 
hypertensive, and they are in agreement with other studies (Berenyiova, 
Drobna, Cebova, Kristek, & Cacanyiova, 2018). 
After a four-week of the lycopene supplemented diet, we observed an 
Fig. 2. Left ventricular hypertrophy (LVH) (A), left ventricle sections stained with Sirius-red (magnification x200) (B), cardiac hydroxyproline content (OH-Pro) (C), 
and cardiac interstitial fibrosis quantification (D) in young and adult spontaneously hypertensive rats (SHR) and SHR treated with 10 mg/kg/day of lycopene (SHR- 
LYC). Values are expressed as mean ± SEM (n = 7). #P < 0.05 and ###P < 0.001 vs. young SHR; *P < 0. 05, **P < 0. 01 and ***P < 0.001 vs. the corresponding SHR 
without treatment. 
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effective reduction on SBP in both young and adult rats. This effect was 
more pronounced in young animals, reaching normal values of blood 
pressure. We have previously reported that lycopene plays an important 
role in regulating blood pressure in other animal models. On the one 
hand it showed antihypertensive action, but not hypotensive effects in 
Wistar rats infused with angiotensin II and on the other hand prevented 
the increase in blood pressure in the metabolic syndrome (Ferreira- 
Santos et al., 2020, 2018). Human studies also show the action of 
lycopene at the cardiovascular level, highlighting the advantages of its 
consumption and no toxic effects (Cheng et al., 2017; Ried & Fakler, 
2011). All of these results could support the usefulness of lycopene in the 
prevention of hypertension. 
Chronic hypertension and aging are typically associated with organs 
hypertrophy and remodeling, in addition to increasing the incidence of 
inflammatory processes. Our results of morphometric and histological 
measures show that cardiac, renal and vascular hypertrophy and fibrosis 
was higher in adult SHR and these parameters were decreased, in both 
young and adult SHR, after 4 weeks of treatment with lycopene. Wang 
and co-workers (Wang et al., 2014) indicated that lycopene improved 
the cardiac function and ventricular remodeling. 
It is important to note that the oxidative stress has a negative effect in 
vascular structure and function. Moreover, several experimental studies 
revealed that the aorta presents vascular remodeling and endothelial 
dysfunction associated with the presence of hypertension and the impact 
of age in SHR (Berenyiova et al., 2018; Zhang et al., 2018). The present 
study confirms that ACh-dependent endothelial relaxation and SNP- 
independent endothelial relaxation decreased significantly in adult 
SHR compared to young rats. Moreover, this reduction in relaxing re-
sponses was accompanied by changes in the morphology of the arteries, 
visible in wall thickening or lumen increase of the older animals. 
Lycopene treatment showed effective action to prevent morphological 
changes, but failed to improve aortic vasodilation. These results are in 
line with previous findings obtained by our group with lycopene and 
astaxanthin, both carotenoids improved the cardiac, renal, and aortic 
hypertrophy and fibrosis, but had no effect on ACh-induced relaxations 
in aortic rings obtained from continuously perfused angiotensin II rats 
and SHR, respectively (Ferreira-Santos et al., 2018; Monroy-Ruiz, 
Fig. 3. Renal hypertrophy (RH) (A), kidney sections stained with Sirius-red (magnification x200) (B), renal hydroxyproline content (OH-Pro) (C), and renal 
interstitial fibrosis quantification (D) in young and adult spontaneously hypertensive rats (SHR) and SHR treated with 10 mg/kg/day of lycopene (SHR-LYC). Values 
are expressed as mean ± SEM (n = 7). #P < 0.05 and ###P < 0.001 vs. young SHR, *P < 0. 05, **P < 0. 01 and ***P < 0.001 vs. the corresponding SHR 
without treatment. 
Table 1 
Effects of lycopene on thoracic aortic wall geometry.   
Young Adult 
Parameters SHR SHR-LYC SHR SHR-LYC 








Wm (µm) 134.0 ± 1.8 115.8 ±
2.2*** 




0.66 ± 0.01 0.58 ± 0.02** 0.83 ± 0.01### 0.71 ± 0.03** 
Wm/L 0.09 ± 0.00 0.08 ±
0.00*** 
0.10 ± 0.00### 0.09 ±
0.00*** 
Internal diameter (L), medial wall thickness (Wm), and medial cross-sectional 
area (CSAm). Values are expressed as mean ± SEM of 7 rats. 
### P < 0.001 vs. young SHR, ** P < 0.01 and *** P < 0.001 vs. the corre-
sponding SHR without treatment. 
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Fig. 4. Histological sections of the aorta stained with hematoxylin-eosin in young (A) and adult (B) spontaneously hypertensive rats (SHR) and SHR treated with 10 
mg/kg/day of lycopene (SHR-LYC). Original magnification x40 and x200. 
Fig. 5. Cumulative concentration–response curves to acetylcholine (ACh) (A) and sodium nitroprusside (SNP) (B) in pre-constricted aortic rings from young and 
adult spontaneously hypertensive rats (SHR) and SHR treated with 10 mg/kg/day of lycopene (SHR-LYC). Values are expressed as mean ± SEM (n = 7). ##P < 0.01 
and ###P < 0.001 vs. young SHR. 
Fig. 6. Generation of vascular superoxide anion (O2
•¡) stimulated by NADPH in aortic rings (A) and assessment of lipid peroxidation through the quantification of 
malondialdehyde (MDA) in plasma (B) from young and adult spontaneously hypertensive rats (SHR) and SHR treated with 10 mg/kg/day of lycopene (SHR-LYC). 
Values are expressed as mean ± SEM (n = 7). #P < 0.05, and ###P < 0.001 vs. young SHR, *P < 0. 05, **P < 0. 01 and ***P < 0.001 vs. the corresponding SHR 
without treatment. 
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Sevilla, Carrón, & Montero, 2011). 
The present study also reveals the beneficial effect of lycopene on 
oxidative stress on this model of hypertension. Oxidative stress occurs 
from the imbalance between ROS production and antioxidant defenses 
and several studies have proven that heart tolerance to oxidative stress 
decreases with age because of a reduction in the concentrations of the 
antioxidant enzymes, contributing to the development of cardiovascular 
alterations (Abete et al., 1999; Adwas, Elsayed, Azab, & Quwaydir, 
2019). The current study shows that the age leads to an increase in 
oxidative stress biomarkers. There is an age-dependent significant in-
crease of MDA plasma levels and O2
•¡ production induced by NADPH. 
Although the adult SHR used in this study did not show differences 
respect to the young ones in markers of antioxidant defenses like SOD 
and GSH-PX, lycopene was able to significantly increase these endoge-
nous defenses, in both groups. 
A recent study also found that similar doses of lycopene increase 
antioxidant defenses as a result of the improvement in activity of cata-
lase, SOD, and GSH-PX in animals with type 2 diabetes mellitus (Zheng, 
Yin, Lu, & Jiang, 2019). It has been reported that lycopene serves as a 
precursor for various oxidative cleavage products and metabolites that 
can interact with multiple transcription factors to overexpress antioxi-
dant and cytoprotective enzymes (Saini, Rengasamy, Mahomoodally, & 
Keum, 2020). 
In both young and adult rats treated with lycopene the O2
•¡ pro-
duction and plasma MDA levels were reduced compared to their con-
trols. These results are in line with those obtained in a previous study 
where we demonstrated that lycopene had a beneficial effect in an 
experimental model of hypertension with a high component of oxidative 
stress, in which the levels of angiotensin II are continually elevated 
(Ferreira-Santos et al., 2018). 
A study, performed in hypertensive patients, demonstrates the action 
of the diet supplemented with tomatoes (vegetable in which lycopene is 
the predominant carotenoid) changes the redox state, increases antiox-
idant enzymes and decreases peroxidation lipid (Bose & Agrawal, 2007). 
In conclusion, hypertension causes cardiovascular complications 
such as endothelial dysfunction, remodeling or oxidative stress, which 
intensify with age and treatment with lycopene improved most of these 
alterations in a similar way in both young and adult animals. 
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Conceptualization, Writing - original draft, Visualization, Supervision. 
Declaration of Competing Interest 
The authors declare that they have no known competing financial 
interests or personal relationships that could have appeared to influence 
the work reported in this paper. 
Acknowledgements 
This work was financed by the University of Salamanca (Spain). 
Pedro Ferreira Santos was the recipient of a fellowship funded by a 
project Art.83/LOU of University of Salamanca. 
Lycopene was kindly supplied by DSM NUTRITIONAL PRODUCTS. 
References 
Abete, P., Napoli, C., Santoro, G., Ferrara, N., Tritto, I., Chiariello, M., … Ambrosio, G. 
(1999). Age-related decrease in cardiac tolerance to oxidative stress. Journal of 
Molecular and Cellular Cardiology, 31(1), 227–236. https://doi.org/10.1006/ 
jmcc.1998.0862. 
Anlar, H. G., & Bacanli, M. (2020). Lycopene as an antioxidant in human health and 
diseases. In Pathology (pp. 247–254). Elsevier. http://dx.doi.10.1016/b978-0-12- 
815972-9.00024-x. 
Arain, M. A., Zhuang, M., Hassan, F.-U., & Saeed, M. (2018). Lycopene: A natural 
antioxidant for prevention of heat-induced oxidative stress in poultry. World’s 
Poultry Science Journal, 74(1), 89–100. https://doi.org/10.1017/ 
S0043933917001040. 
Babio, N., Toledo, E., Estruch, R., Ros, E., Martínez-González, M. A., Castañer, O., … 
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